XSTOSCOL
Market cap1mUSD
Dec 20, Last price
0.08SEK
1D
-0.61%
1Q
-44.18%
IPO
-99.03%
Name
Scandion Oncology A/S
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
31.76%
Rev. gr., 5y
%
Revenues
0k
Net income
-39m
L-48.89%
CFO
-51m
L-27.04%
Earnings
Feb 28, 2025
Profile
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
Valuation
Title DKK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | 45,803 | 72,076 | 50,847 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (45,803) | (72,076) | (50,847) | ||||
NOPBT Margin | |||||||
Operating Taxes | 5,500 | (5,500) | (5,508) | ||||
Tax Rate | |||||||
NOPAT | (51,303) | (66,576) | (45,339) | ||||
Net income | (39,204) -48.89% | (76,700) 48.34% | (51,705) 217.81% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 53,545 | 150,690 | |||||
BB yield | |||||||
| Debt | |||||||
Debt current | 499 | 776 | 723 | ||||
Long-term debt | 499 | 2,418 | 1,723 | ||||
Deferred revenue | |||||||
Other long-term liabilities | (1,000) | 84 | |||||
Net debt | (25,522) | (74,411) | (103,264) | ||||
| Cash flow | |||||||
Cash from operating activities | (50,668) | (69,443) | (49,798) | ||||
CAPEX | (414) | (318) | |||||
Cash from investing activities | 288 | (389) | (485) | ||||
Cash from financing activities | (705) | 41,727 | 150,179 | ||||
FCF | (53,901) | (67,231) | 97,804 | ||||
| Balance | |||||||
Cash | 26,520 | 77,605 | 105,710 | ||||
Long term investments | |||||||
Excess cash | 26,520 | 77,605 | 105,710 | ||||
Stockholders' equity | (201,886) | (162,681) | (86,611) | ||||
Invested Capital | 233,507 | 234,604 | 192,459 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 40,707 | 42,928 | 33,636 | ||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | (44,834) | (71,194) | (50,243) | ||||
EV/EBITDA | |||||||
Interest | 495 | 767 | |||||
Interest/NOPBT | |||||||